Securitization of Intellectual Property as a Funding Alternative

Table of Contents

1. INTRODUCTION

2. CHALLENGES OF CORPORATE FUNDING

3. INTRODUCTION TO INTELLECTUAL PROPERTY

3.1 Definition and classification

3.2 Different types of intellectual property

3.2.1 Patents

3.2.2 Trademarks

3.2.3 Copyrights

3.2.4 Other types of intellectual property

3.3 Economic weight of intellectual property

4. INTELLECTUAL PROPERTY: A NEW ASSET CLASS IN SECURITIZATION?

4.1 Securitization – the tool in brief

4.2 Definition of IP in the securitization arena

4.3 Market overview

4.4 Benefits and hindrances of IP securitization

4.4.1 Corporates

4.4.2 Investors

4.4.3 Banks

4.4.4 Hindrances of market growth

4.5 Funding conditions

4.6 Case Study: BioPharma Royalty Trust

5. IDENTIFICATION OF SECURITIZABLE INTELLECTUAL PROPERTY

6. MAJOR ISSUES IN THE STRUCTURING PROCESS

6.1 Transaction structure

6.1.1 Introductory remarks

6.1.2 Direct IP securitization

6.1.2.1 IP true sale structure

6.1.2.2 IP sale and lease-back structures

6.1.3 Indirect IP securitization

6.1.3.1 Basic IP royalties structure

6.1.3.2 Conditional assignment structure

6.1.3.3 Secured IP loan structure

6.2 Servicing

6.3 Credit enhancement

6.3.1 Introductory remarks

6.3.2 Internal credit enhancement tools

6.3.3 External credit enhancement tools

7. EXECUTION OF AN IP BACKED SECURITIZATION

7.1 Introductory remarks

7.2 Transaction preparation

7.3 Documentation

7.4 Rating Process

7.5 Marketing and distribution

7.6 Other borrower obligations

8. CONCLUSION

Research Objectives and Key Themes

The primary objective of this thesis is to explore and introduce the securitization of intellectual property (IP) as a viable funding alternative for corporations, particularly those with significant intangible assets but limited access to traditional capital markets. The research addresses how IP can be identified, structured, and utilized as collateral to improve funding conditions, manage liquidity, and optimize corporate liability structures.

• The theoretical foundation and classification of various intellectual property rights.
• Mechanisms and requirements for transitioning IP into a securitizable asset class.
• Benefits and associated risks for originators, investors, and banking institutions.
• Structuring techniques and credit enhancement strategies specific to IP transactions.
• Practical application through case studies like the BioPharma Royalty Trust.

Excerpt from the Book

Summary of Chapters

1. INTRODUCTION: This chapter establishes the importance of intellectual property in the modern economy and outlines the motivations for exploring IP securitization as a funding tool.

2. CHALLENGES OF CORPORATE FUNDING: Discusses the fundamentals of corporate treasury, focusing on how companies manage liquidity and interest rate risks through equity, debt, and mezzanine financing.

3. INTRODUCTION TO INTELLECTUAL PROPERTY: Provides a comprehensive overview of IP definitions, classifications, and the varying legal protection methods for patents, trademarks, and copyrights.

4. INTELLECTUAL PROPERTY: A NEW ASSET CLASS IN SECURITIZATION?: Analyzes the market status of IP securitization, evaluating benefits for corporates and investors while identifying key hindrances to market growth.

5. IDENTIFICATION OF SECURITIZABLE INTELLECTUAL PROPERTY: Introduces a scoring tool to evaluate the eligibility of specific IP assets based on cash-flow history, diversification, and market position.

6. MAJOR ISSUES IN THE STRUCTURING PROCESS: Examines transaction structures (direct vs. indirect), servicing requirements, and specific credit enhancement tools used in IP deals.

7. EXECUTION OF AN IP BACKED SECURITIZATION: details the practical steps of a transaction, from initial preparation and legal documentation to the rating process and distribution strategy.

8. CONCLUSION: Synthesizes the findings of the thesis, assessing the overall potential and limitations of IP securitization as a mainstream corporate funding instrument.

Key Keywords

Intellectual Property, Securitization, Corporate Funding, Asset-Backed Securities, IP Licensing, Patent Securitization, Trademark Securitization, Royalty Streams, Credit Enhancement, Structural Finance, Risk Assessment, Valuation Methods, Cash-Flow Analysis, Collateralization, Knowledge Economy.

Frequently Asked Questions

What is the fundamental purpose of this thesis?

The work aims to examine whether intellectual property can be successfully used as collateral in securitization transactions to provide companies with an alternative, efficient funding source.

What are the core thematic areas discussed?

The thesis covers the nature of IP assets, the mechanisms of securitization, the challenges corporate treasuries face in funding, and the practical issues involved in structuring and rating IP-backed deals.

What is the primary research goal?

The goal is to determine if IP securitization can effectively bridge the gap between a company's valuable intangible assets and its need for capital, particularly when traditional funding is restrictive.

Which scientific methods are applied?

The author utilizes a descriptive and analytical approach, drawing on market data, existing securitization case studies (like BioPharma Royalty Trust), and theoretical models from financial literature.

What topics are covered in the main section of the work?

The main part analyzes the definition and classification of IP, the specific eligibility criteria for securitization, the different transaction structures (true sale, indirect), and the complex process of rating and marketing these deals.

What are the primary keywords that define this study?

Core keywords include intellectual property, asset-backed securities (ABS), corporate treasury, securitization, risk decoupling, and IP valuation.

How does the author define an 'IP deal' for the scope of this research?

An 'IP deal' is defined as any transaction where the intellectual property collateral represents more than 50% of the asset's total value.

Why is IP securitization currently considered a difficult or 'exotic' funding path?

It is difficult due to the high costs of structuring, the complexity of legal documentation, the reliance on unpredictable public taste, and the lack of standardization in valuation compared to traditional assets like mortgages.

What is the significance of the BioPharma Royalty Trust case study?

This case serves as a prime example of a successful patent-backed deal, illustrating how specific legal and credit enhancement structures can mitigate the high risks associated with drug development and license royalties.